These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 33794182)

  • 1. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.
    Esteban-Cantos A; Rodríguez-Centeno J; Barruz P; Alejos B; Saiz-Medrano G; Nevado J; Martin A; Gayá F; De Miguel R; Bernardino JI; Montejano R; Mena-Garay B; Cadiñanos J; Florence E; Mulcahy F; Banhegyi D; Antinori A; Pozniak A; Wallet C; Raffi F; Rodés B; Arribas JR;
    Lancet HIV; 2021 Apr; 8(4):e197-e205. PubMed ID: 33794182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.
    Schoepf IC; Esteban-Cantos A; Thorball CW; Rodés B; Reiss P; Rodríguez-Centeno J; Riebensahm C; Braun DL; Marzolini C; Seneghini M; Bernasconi E; Cavassini M; Buvelot H; Thurnheer MC; Kouyos RD; Fellay J; Günthard HF; Arribas JR; Ledergerber B; Tarr PE;
    Lancet Healthy Longev; 2023 May; 4(5):e211-e218. PubMed ID: 37148893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
    Bernardino JI; Mocroft A; Mallon PW; Wallet C; Gerstoft J; Russell C; Reiss P; Katlama C; De Wit S; Richert L; Babiker A; Buño A; Castagna A; Girard PM; Chene G; Raffi F; Arribas JR;
    Lancet HIV; 2015 Nov; 2(11):e464-73. PubMed ID: 26520926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
    Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
    J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus-Infected Recipients of Long-term Antiretroviral Treatment.
    Esteban-Cantos A; Montejano R; Rodríguez-Centeno J; Saiz-Medrano G; De Miguel R; Barruz P; Bernardino JI; Mena-Garay B; Cadiñanos J; Jiménez-González M; Nevado J; Valencia E; Mayoral-Muñoz M; Arribas JR; Rodés B
    J Infect Dis; 2022 Jan; 225(2):287-294. PubMed ID: 34166509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
    Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C; Saillard J; Wallet C; Jansson PO; Allavena C; Van Leeuwen R; Delfraissy JF; Vella S; Chêne G; Pozniak A;
    Lancet; 2014 Nov; 384(9958):1942-51. PubMed ID: 25103176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
    Lambert-Niclot S; George EC; Pozniak A; White E; Schwimmer C; Jessen H; Johnson M; Dunn D; Perno CF; Clotet B; Plettenberg A; Blaxhult A; Palmisano L; Wittkop L; Calvez V; Marcelin AG; Raffi F;
    J Antimicrob Chemother; 2016 Apr; 71(4):1056-62. PubMed ID: 26702926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
    Dickinson L; Gurjar R; Stöhr W; Bonora S; Owen A; D'Avolio A; Cursley A; Molina JM; Fäetkenheuer G; Vandekerckhove L; Di Perri G; Pozniak A; Richert L; Raffi F; Boffito M;
    J Antimicrob Chemother; 2020 Mar; 75(3):628-639. PubMed ID: 31754703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HIV infection and antiretroviral therapy initiation on genome-wide DNA methylation patterns.
    Esteban-Cantos A; Rodríguez-Centeno J; Silla JC; Barruz P; Sánchez-Cabo F; Saiz-Medrano G; Nevado J; Mena-Garay B; Jiménez-González M; de Miguel R; Bernardino JI; Montejano R; Cadiñanos J; Marcelo C; Gutiérrez-García L; Martínez-Martín P; Wallet C; Raffi F; Rodés B; Arribas JR;
    EBioMedicine; 2023 Feb; 88():104434. PubMed ID: 36640455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.
    Ammassari A; Stöhr W; Antinori A; Molina JM; Schwimmer C; Domingo P; Thalme A; Di Pietro M; Wallet C; Pozniak A; Richert L; Raffi F;
    J Acquir Immune Defic Syndr; 2018 Dec; 79(4):481-490. PubMed ID: 30365452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide association studies identify novel genetic loci for epigenetic age acceleration among survivors of childhood cancer.
    Dong Q; Song N; Qin N; Chen C; Li Z; Sun X; Easton J; Mulder H; Plyler E; Neale G; Walker E; Li Q; Ma X; Chen X; Huang IC; Yasui Y; Ness KK; Zhang J; Hudson MM; Robison LL; Wang Z
    Genome Med; 2022 Mar; 14(1):32. PubMed ID: 35313970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
    Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Aging and Rheumatoid Arthritis.
    Mukherjee N; Harrison TC
    J Gerontol A Biol Sci Med Sci; 2024 Jan; 79(1):. PubMed ID: 37698382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
    Alejos B; Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Schwimmer C; Bernardino JI; Rodes B; Esser S; Goujard C; Sarmento-Castro R; De Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
    HIV Med; 2019 Nov; 20(10):691-698. PubMed ID: 31532902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.
    Raffi F; Gaultier A; Pozniak A; Molina JM; Jessen H; Antinori A; Soria A; Cavellec M; Le Thuaut A; Ningre M; de Wit S
    J Antimicrob Chemother; 2020 Jun; 75(6):1618-1622. PubMed ID: 32211883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Neighborhood Deprivation With Epigenetic Aging Using 4 Clock Metrics.
    Lawrence KG; Kresovich JK; O'Brien KM; Hoang TT; Xu Z; Taylor JA; Sandler DP
    JAMA Netw Open; 2020 Nov; 3(11):e2024329. PubMed ID: 33146735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decelerated epigenetic aging associated with mood stabilizers in the blood of patients with bipolar disorder.
    Okazaki S; Numata S; Otsuka I; Horai T; Kinoshita M; Sora I; Ohmori T; Hishimoto A
    Transl Psychiatry; 2020 May; 10(1):129. PubMed ID: 32366819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.